I’ve talked about $TPR before, and I’m sticking to my guns here. They tried to pull off a Louis Vuitton $LVMUY, but let’s be real: it’s not hitting the mark. They brought Stuart Weitzman in 2015 and Kate Spade in 2018 into the fold, thinking they could sprinkle some of that Coach magic on them.… Read More Magic Touch or Misstep? Reflections on Tapestry $TPR
Invitae Corporation (NVTA) faces significant challenges in addressing its liquidity concerns. The firm is exploring multiple strategies to stabilize its financial and operational footing. These strategies encompass potential capital raising, asset divestitures, strategic refocusing on core business and R&D activities, curtailment of capital spending, operating cost reductions, and managing debt commitments. The company’s current cash… Read More Invitae’s High-Stakes Financial Maneuvering: Dilution Might Not Be That Bad
CASGEVY approval CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG (CRSP) and Vertex (VRTX) specifically designed for the treatment of sickle cell disease (SCD) in individuals aged 12 and older who experience frequent vaso-occlusive crises (VOCs). Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved… Read More A primer on the impact of gene therapies and CASGEVY on CRISPR AG and the industry
Given China’s significant role as a key player in the global economy, I maintain a vigilant and analytical approach to Professor Michael Pettis’ insights on its economic strategies. Pettis has long maintained that China’s reliance on supply-side stimulus is a misstep. This is pivotal as China, being the world’s second-largest economy, grapples with sluggish growth… Read More China’s Economic Crossroads: Navigating the Delicate Balance
As we navigate the currents of today’s financial markets, we’re witnessing a striking contrast between the resilience of equities and the cautious stance of the bond market. Equity markets, it seems, are choosing to overlook looming challenges, clinging to a narrative of a ‘soft landing’ for the economy. On the other side, bond markets are… Read More Loose thoughts in a time of uncertainty
The macro landscape is painting a fascinating picture of the inflationary environment, especially when we dive deep into the underlying narratives. The NBER folks help us get a more precise picture of what caused inflation. They concluded the following: 1. First, let’s not underestimate the magnitude of the U.S.’s fiscal response to the pandemic. With… Read More Dissecting the Causes of Inflation
Executive Summary: Grayscale Investments’ recent court ruling in favor of launching the first-ever Bitcoin ETF in the U.S. is a watershed moment for the cryptocurrency ecosystem. Beyond the immediate market reaction, this event points towards a maturing regulatory environment and sets a potential precedent for the broader adoption of crypto-focused financial products. Regulatory Inconsistencies: Upon… Read More Quick Takes: Grayscale’s Victory & The Evolution of Cryptocurrency Regulation
Wealth transfers have, throughout history, acted as a cornerstone of societal evolution. These transfers are not mere shifts of assets from one hand to another; they represent changes in power dynamics, socio-economic structures, and often herald a new epoch in human civilization. The French Revolution: A Primer on Wealth Transfer Consider the French Revolution, a… Read More A Macro Perspective on Wealth Transfers: From the French Revolution to Bitcoin
In our constant endeavor to find companies ready to launch products and services in the gene therapy space, we come across Vertex Pharmaceuticals and CRISPR Therapeutics, who alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. Now, to bring this into context, the recent report by… Read More Gene Therapy Breakthroughs on the Horizon
The macro narrative is missing a giant piece of the puzzle. Dive deep into the data, and an understated deflationary shock from China becomes evident. Surprisingly, in the face of a 6% depreciation of the yuan against the USD over the past 12 months – an event that, by all accounts, should be inflationary –… Read More Macro Note: The Deflationary Dragon
Investment Gems 